OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Clinical trial NCT06016738 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06016738
- Sponsor
- Olema Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-16
- Primary completion
- 2026-10-31
- Enrollment
- 510
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.